VK2735
Investigational dual agonist (GLP-1 + GIP) from Viking Therapeutics, with both a weekly injectable and a once-daily oral form in development.
VK2735: Investigational dual agonist (GLP-1 + GIP) from Viking Therapeutics, with both a weekly injectable and a once-daily oral form in development. VK2735 is an experimental weight-loss drug from Viking Therapeutics.
VK2735 is an experimental weight-loss drug from Viking Therapeutics. It works on two gut-hormone receptors (GLP-1 and GIP) to cut appetite, the same combo as Tirzepatide. The notable part is the pill version: in early trials a once-daily tablet got close to the results of the injection. It is still in testing and not approved.
Investigational. The injectable is in Phase 3 (begun 2025); the oral form is expected to enter Phase 3 around late 2026. Pivotal readouts are not expected before 2027. Not approved.
GLP-1/GIP agonists are not specifically named on the WADA Prohibited List, but as an unapproved investigational substance VK2735 is likely prohibited under S0 (non-approved substances) for tested athletes, so treat it as banned if you compete.
Not available by prescription. Access is trial-only through Viking Therapeutics' clinical program.
Who it's for
- โPeople following the oral-GLP-1 race who want a needle-free option
- โUsers tracking next-generation weight-loss compounds before approval
- โAnyone comparing it to Tirzepatide's GLP-1/GIP mechanism
What to expect
- Week 1
Trial data: appetite drops early, mild-to-moderate nausea is the most common effect at the start.
- Week 4
Progressive weight loss across all doses in the Phase 2 VENTURE program.
- Week 8
Loss kept building with no plateau seen by the 13-week trial endpoint.
Looking at VK2735? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for VK2735.
Open calculator โ - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide โ - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account โ
Dosing protocol
Stacks well with
Side effects
When NOT to use
- โ Class-based caution (VK2735 has no FDA label yet): personal or family history of medullary thyroid carcinoma or MEN-2
- โ Class-based caution / likely trial exclusion: pancreatitis history
- โ Pregnancy / nursing
Bloodwork to monitor
- โข Lipid panel
- โข Liver enzymes (ALT/AST)
- โข A1C if metabolic context
Common mistakes
- โข Treating early trial data as a finished safety profile, it is Phase 2
- โข Assuming the oral form is interchangeable with the injectable, the exposure differs
- โข Sourcing an investigational compound where identity and purity cannot be verified
What it actually is
VK2735 is an investigational GLP-1 and GIP dual agonist from Viking Therapeutics, developed in two forms: a weekly injection and a once-daily tablet. It is not approved anywhere and access is trial-only. The evidence index finds one indexed paper, which is what an early-stage compound looks like โ the phase 2 results that generated the attention around it were reported largely by press release before publication.
The same two-receptor combination as tirzepatide: GLP-1 and GIP together, reducing appetite and slowing gastric emptying, with the GIP arm associated with more weight loss than GLP-1 alone. The genuinely different thing about VK2735 is the oral programme. An orally available peptide-like drug at weight-management doses would remove the injection barrier entirely, and the oral phase 2 is where its gastrointestinal dropout rate showed up most clearly.
Forms, and which is which
The VENTURE programme titrated weekly over 13 weeks. Identity, dose and monitoring are known only here.
Verdict: The only defensible access.
A separate phase 2 ran once daily. Exposure differs from the injection, so the two are not interchangeable at the same dose.
Verdict: A different drug exposure, not a convenience swap.
No approved product exists to compare against, so identity, potency and sterility cannot be verified.
Verdict: Unverifiable contents outside any lawful route.
Combines an investigational compound with others, making any effect unattributable.
Verdict: Several unknowns at once.
What it is claimed to do, graded
A phase 2 randomised trial of the weekly subcutaneous form has now been published. Real, and short: 13 weeks is long enough to show weight change and not long enough to say much else.
A separate oral phase 2 ran, and gastrointestinal effects drove notable dropouts, more at the highest dose. The concept has support and the tolerability question is unresolved.
No head-to-head trial exists. Cross-trial comparison at 13 weeks against 72-week programmes is not a comparison.
The published trial ran 13 weeks. Nothing longer has been reported.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- โข A published randomised phase 2 trial exists, which most investigational compounds in this catalog lack
- โข The oral programme addresses the single biggest adherence barrier in the class
- โข Weekly dosing for the injectable
- โข Same well-understood dual-receptor mechanism as an approved drug
- โข Not approved anywhere, trial-only access
- โข One indexed paper โ the evidence base is genuinely thin, whatever the share price says
- โข 13-week trials cannot establish durability or safety
- โข The oral form's gastrointestinal dropout rate was substantial
- โข Nothing sold outside a trial can be verified
When to stop
- โข Severe persistent abdominal pain radiating to the back
- โข Vomiting that prevents keeping fluids down
- โข A new neck lump, hoarseness or difficulty swallowing
- โข Appetite suppression severe enough that protein intake has collapsed
- โข Pregnancy
Interactions
Additive glucose lowering expected from the mechanism. No approved interaction labelling exists, so no list can be treated as complete.
No added benefit, multiplied gastrointestinal effects.
Delayed gastric emptying alters absorption rate.
Compounds nausea, which was already the limiting effect in the oral trial.
General weight-loss guidance, not a VK2735 trial finding.
Is this for you?
- โข Participation in an authorised clinical trial is the only context in which this is lawfully available
- โข Anyone following where the oral incretin programmes are heading
- โข You want an approved medicine with a known safety profile
- โข Personal or family history of medullary thyroid carcinoma or MEN-2
- โข You are pregnant or nursing
- โข You are treating press-release results as a finished evidence base
The one number
Sources for the claims above
- Phase 2 randomised trial of weekly subcutaneous VK2735 for weight management
- Class context: GIP and GLP-1 dual agonism in type 2 diabetes
- Class context: head-to-head dual agonist versus GLP-1 alone
The Pepdex take
Pepdex take: the oral form is the part worth watching. An everyday tablet that landed near injectable results in Phase 2 is a real story for people who will never inject, though the oral arm also saw meaningful dropouts from stomach side effects at higher doses, so 'well tolerated' has an asterisk. It is dual GLP-1/GIP, the same receptor combo as Tirzepatide, not the triple-agonist route Retatrutide takes. It is investigational: the injectable is already in Phase 3 and the oral form is expected to enter Phase 3 around late 2026, with pivotal readouts not before 2027. There is no approved dosing and source quality is a real risk. Watch the data, do not treat it as a settled compound yet.
New to VK2735? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about VK2735 or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week โFrequently asked
What is VK2735?+
Is VK2735 FDA approved?+
Is VK2735 legal?+
Is VK2735 banned by WADA?+
Are you still natty after taking VK2735?+
Do doctors prescribe VK2735?+
What's the typical dose of VK2735?+
What are the side effects of VK2735?+
How long until VK2735 starts working?+
What can you stack with VK2735?+
Where do people get VK2735?+
VK2735 vs Tirzepatide, which is better?+
VK2735 vs Retatrutide, which is better?+
VK2735 vs Semaglutide, which is better?+
Common questions about VK2735
Head-to-head with VK2735
Tracked alongside VK2735
Same goal, different aisle โ each graded on its own evidence in the Pepdex catalog.
More in Fat Loss
Strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound.
The original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist.
Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.
Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.